Lilly's Foundayo: New Oral GLP-1 Drug for Weight Loss

Eli Lillys new oral GLP-one drug, Foundayo, is making waves in the weight loss market, approved by the FDA on April 1st. This daily pill, similar to Lillys injectable Zepbound, shows promising results in head-to-head trials against Novo Nordisks Wegovy. With high demand and safety, Foundayo is attracting new patients, rather than stealing users from existing GLP-one medications. Lillys pipeline continues to expand with retatrutide in late trials, potentially opening up new markets and boosting revenue. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/20b95e44fc26e4a3